Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-cash Items (2019 - 2025)

Outlook Therapeutics (OTLK) has disclosed Non-cash Items for 4 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 33.63% to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 million, a 33.63% decrease, with the full-year FY2025 number at $2.0 million, changed N/A from a year prior.
  • Non-cash Items was $4.3 million for Q4 2025 at Outlook Therapeutics, up from $2.0 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $6.5 million in Q4 2024 to a low of $1200.0 in Q2 2025.